Home > Events & News > Barcelona Global Update > A new drug for patients with advanced ovarian cancer achieves for the first time a 3-year survival in 50% of patients. Hospital Vall d'Hebron has participated in the clinical trial.
A new drug for patients with advanced ovarian cancer achieves for the first time a 3-year survival in 50% of patients. Hospital Vall d'Hebron has participated in the clinical trial.
